XMAD
ATRY
Market cap216mUSD
Jul 22, Last price
2.50EUR
1D
2.46%
1Q
-13.49%
Jan 2017
68.92%
IPO
48.81%
Name
Atrys Health SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular pathology, and genetics, supplemented by offerings such as diagnostic second opinions, a comprehensive test directory, and support for clinical trials and research & development. The company effectively utilizes telemedicine to deliver its expertise in medical specialties including radiology, cardiology, ophthalmology, and dermatology. Furthermore, Atrys Health administers radiotherapy and is engaged in the development of innovative therapeutic approaches and diagnostic instruments. The organization operated as Althia Health, S.L. before rebranding to Atrys Health, S.A. in May 2016.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||